Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,586 | 540 | 2,006 |
| Samples | 2,129 | 448 | 1,649 |
| Peptides | 1,675 | 326 | 1,398 |
Function
LAMA1 · Laminin subunit alpha 1
This gene encodes one of the alpha 1 subunits of laminin. The laminins are a family of extracellular matrix glycoproteins that have a heterotrimeric structure consisting of an alpha, beta and gamma chain. These proteins make up a major component of the basement membrane and have been implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling, neurite outgrowth and metastasis. Mutations in this gene may be associated with Poretti-Boltshauser syndrome. [provided by RefSeq, Sep 2014].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000389658 | P25391 | 2,586 | 1,675 |
Gene Properties
Recurrent Mutations
All 1675 amino-acid changes on canonical ENST00000389658 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LAMA1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LAMA1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 17/40 42% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 5/26 19% | 0/0 0% |
| Endometrial Carcinoma | 12/42 29% | 57/612 9% |
| Melanoma | 32/210 15% | 184/1899 10% |
| Gastric Carcinoma | 18/74 24% | 169/1809 9% |
| Oral Cavity Carcinoma | 5/54 9% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 65/304 21% | 89/1390 6% |
| Other Solid Cancers | 10/94 11% | 134/1515 9% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 10/57 18% | 58/810 7% |
| Acute Myeloid Leukemia | 7/90 8% | 0/0 0% |
| Glioblastoma | 7/98 7% | 0/0 0% |
| Colorectal Carcinoma | 42/143 29% | 186/3239 6% |
| Esophageal Carcinoma | 2/23 9% | 51/769 7% |
| Hodgkins Lymphoma | 2/16 12% | 7/122 6% |
| Neuroendocrine Tumour | 29/154 19% | 11/577 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 7/133 5% |
| Cervical Carcinoma | 7/35 20% | 17/422 4% |
| Bladder Carcinoma | 3/58 5% | 50/956 5% |
| Chordoma | 1/7 14% | 0/13 0% |
| Biliary Tract Carcinoma | 5/54 9% | 44/950 5% |
| Hepatocellular Carcinoma | 10/46 22% | 87/2210 4% |
| Small Cell Lung Carcinoma | 0/9 0% | 32/752 4% |
| Esophageal Squamous Cell Carcinoma | 17/51 33% | 90/2550 4% |
| Plasma Cell Myeloma | 7/44 16% | 7/305 2% |
| Osteosarcoma | 6/45 13% | 2/166 1% |
| Head and Neck Carcinoma | 6/85 7% | 54/1574 3% |
| Germ Cell Tumour | 4/25 16% | 2/169 1% |
| Mesothelioma | 5/62 8% | 2/165 1% |
| Burkitts Lymphoma | 7/32 22% | 0/196 0% |
Mutation Distribution
Where LAMA1 is mutated · all tissues, split by cell line vs tissue
How many mutations in LAMA1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,586 mutations in LAMA1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|